We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 10 for:    XVIVO

Non-ischemic Preservation of the Donor Heart in Heart Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03991923
Recruitment Status : Recruiting
First Posted : June 19, 2019
Last Update Posted : August 23, 2022
Sponsor:
Information provided by (Responsible Party):
XVIVO Perfusion

Brief Summary:
The study intends to compare standard ischemic cold static storage (ICSS) of retrieved hearts intended to be transplanted, to non-ischemic heart preservation (NIHP) in a randomized clinical multicentre trial. The primary hypothesis is that the non-ischemic hypothermic cardioplegic preservation (NIHP) is safe and superior to ischemic cold static storage (ICSS) of donor hearts. The study will investigate the safety and superiority of the new methodology in terms of improved immediate and prolonged organ function in adult heart transplanted patients.

Condition or disease Intervention/treatment Phase
Heart Transplantation Device: XVIVO heart preservation devices Device: Standard ICSS Not Applicable

Detailed Description:
This study will investigate if non-ischemic heart preservation (NIHP) with the XVIVO heart preservation devices could improve clinical outcome of patients receiving hearts after use of the technology compared to after use of standard cold ischemic preservation. This will be investigated in a European multicentre randomized controlled clinical trial. For technical reasons, blinding to the involved clinical personnel is not possible, however, biopsies will be blinded to study pathologists. The trial will include 202 recipients that have been randomized through their heart donor. The primary outcome of the study is a clinically relevant composite including graft survival, primary graft dysfunction, rejection and use of circulatory mechanical support, within 30 days and also including Cardiac Allograft Vasculopathy within 12 months. As secondary outcomes, molecular markers related to cardiac injury CKMB, ProBNP and TNI will be investigated as well as markers of the inflammatory response. Safety aspects such as effect on other organs and machine defects will also be monitored. The study population is adults, listed for heart transplantation and donors accepted as heart donors according to standard hospital procedures. Specific recipient exclusion criteria related to pre-transplant ECMO support, patients undergoing pre-transplant desensitization protocol, patients with Grown-Up Congenital Heart Disease, patients with severe kidney or liver dysfunction, patients with septicaemia, and patients diagnosed with Systemic Lupus Erythematous, sarcoidosis or amyloidosis are excluded. Cardiac death donors and donors with previous sternotomy are excluded. The study hypothesis is that NIHP better preserves the endothelium and myocyte function of the heart resulting in improved short- and medium-term recipient outcome, without inducing any new significant risks to the retrieved heart or the recipient. This is believed to be accomplished through continuous oxygenation of the heart via perfusion of the coronary arteries using an optimized preservation solution, mimicking the normal environment for the endothelium.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 202 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Non-ischemic Preservation of the Donor Heart in Heart Transplantation - a Randomized, Controlled, Multicenter Trial
Actual Study Start Date : November 25, 2020
Estimated Primary Completion Date : January 31, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Non-ischemic heart preservation (NIHP)
Continous cold cardioplegic perfusion of hearts
Device: XVIVO heart preservation devices
The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.

Active Comparator: Ischemic cold static storage (ICSS)
Standard preservation technique
Device: Standard ICSS
Cold static preservation using standard preservation solution




Primary Outcome Measures :
  1. 30 days mortality and 30 days graft dysfunction [ Time Frame: 30 days ]
    The Primary End-Point is defined as time-to-first-event of cardiac related death, moderate or severe primary graft dysfunction of the left ventricle or primary graft dysfunction of the right ventricle (according to Kobashigawa et al., 2014), acute cellular rejection ≥2R (according to Stewart et al., 2005) or graft failure (use of mechanical circulatory support or retransplantation) within 30 days.


Secondary Outcome Measures :
  1. 1 year mortality and 1 year graft dysfunction [ Time Frame: 1 year ]
    The key secondary endpoint is defined as time-to-first-event of either any cause of death, moderate or severe PGD-LV or PGD-RV (according to Kobashigawa et al., 2014), acute cellular rejection ≥2R (according to Stewart et al., 2005) or graft failure (use of mechanical circulatory support or retransplantation) or CAV ≥ 1 (according to Mehra, 2010) within 12 months.

  2. 30 days and 1 year mortality and graft dysfunction [ Time Frame: 30 days and 1 year ]
    The individual variables included in the composite primary endpoint at 30 days and 1 year analyzed as time-to-first-event.

  3. CKMB [ Time Frame: 3 days ]
    Creatine kinase MB (CKMB) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal

  4. TnI [ Time Frame: 3 days ]
    Tropinin I (TnI) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal

  5. ProBNP [ Time Frame: 3 days ]
    Pro Brain Natriuretic Protein (ProBNP) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal

  6. Stay in ICU [ Time Frame: 1 year ]
    Length of Stay at Intensive Care Unit, reported as number of days

  7. Cardiac Transplant Events [ Time Frame: 1 year ]
    Incidence of Major Adverse Cardiac Transplant Events

  8. Postoperative use of mechanical circulatory support [ Time Frame: 1 year ]
    Incidence of use of postoperative mechanical circulatory support, reported as number of days

  9. Postoperative duration of mechanical circulatory support [ Time Frame: 1 year ]
    Duration of use of postoperative mechanical circulatory support, reported as number of days

  10. Overall success/failure 30 days [ Time Frame: 30 days ]
    Success is defined as a recipient that are transplanted and alive at 30 days without any of the complication in the primary endpoint before 30 days.

  11. Overall success/failure 1 year [ Time Frame: 1 year ]
    Success is defined as a recipient that are transplanted and alive at 1 year without any of the complication given in key secondary endpoint before 1 year.

  12. ECHO data (Left ventricular ejection fraction) [ Time Frame: 24 hours ]
    ECHO data with Left ventricular ejection fraction in percentage within 24 hours after transplantation

  13. ECHO data (Left ventricular ejection fraction) [ Time Frame: 1 week ]
    ECHO data with Left ventricular ejection fraction in percentage 1 week after transplantation

  14. ECHO data (Left ventricular ejection fraction) [ Time Frame: 6 months ]
    ECHO data with Left ventricular ejection fraction in percentage 6 months after transplantation

  15. ECHO data (Left ventricular ejection fraction) [ Time Frame: 1 year ]
    ECHO data with Left ventricular ejection fraction in percentage 1 year after transplantation

  16. ECHO data (Right ventricular ejection fraction) [ Time Frame: 24 hours ]
    ECHO data with Right ventricular ejection fraction in percentage within 24 hours after transplantation

  17. ECHO data (Right ventricular ejection fraction) [ Time Frame: 1 week ]
    ECHO data with Right ventricular ejection fraction in percentage 1 week after transplantation

  18. ECHO data (Right ventricular ejection fraction) [ Time Frame: 6 months ]
    ECHO data with Right ventricular ejection fraction in percentage 6 months after transplantation

  19. ECHO data (Right ventricular ejection fraction) [ Time Frame: 1 year ]
    ECHO data with Right ventricular ejection fraction in percentage 1 year after transplantation

  20. ECHO data (Tricuspid annular plane systolic excursion) [ Time Frame: 24 hours ]
    ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm within 24 hours after transplantation

  21. ECHO data (Tricuspid annular plane systolic excursion) [ Time Frame: 1 week ]
    ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 1 week after transplantation

  22. ECHO data (Tricuspid annular plane systolic excursion) [ Time Frame: 6 months ]
    ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 6 months after transplantation

  23. ECHO data (Tricuspid annular plane systolic excursion) [ Time Frame: 1 year ]
    ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 1 year after transplantation


Other Outcome Measures:
  1. Serious adverse device effects [ Time Frame: 1 year ]
    Incidence of any serious adverse device effects.

  2. Adverse device effects [ Time Frame: 1 year ]
    Incidence of any adverse device effects

  3. Device dysfunction resulting in loss of transplantable heart [ Time Frame: 12 hours ]
    Number of transplantable hearts lost due to device dysfunction

  4. Intra operative details; duration of ECC [ Time Frame: 12 hours ]
    Duration of ECC in minutes

  5. Intra operative details; duration of cross clamp [ Time Frame: 12 hours ]
    Duration of cross clamp in minutes

  6. Intra operative details; duration of surgery [ Time Frame: 12 hours ]
    Duration of surgery in minutes

  7. Intra operative details; attempts to wean off ECC [ Time Frame: 12 hours ]
    Number of attempts to wean off ECC

  8. Intra operative details; need for inotropic support [ Time Frame: 12 hours ]
    Need for inotropic support (inotropic score)

  9. Intra operative details; need for pulmonary vasodilator [ Time Frame: 12 hours ]
    Need for pulmonary vasodilator

  10. Intra operative details; defibrillations [ Time Frame: 12 hours ]
    Number of defibrillations

  11. Intra operative details; arryhythmias [ Time Frame: 12 hours ]
    Occurence of arryhythmias

  12. Intra operative details; conduction abnormalities [ Time Frame: 12 hours ]
    Number of conduction abnormalities

  13. Intra operative details; Left ventricular ejection fraction (LVEF) [ Time Frame: 12 hours ]
    LVEF in percentage

  14. Intra operative details; Right ventricular ejection fraction (RVEF) [ Time Frame: 12 hours ]
    RVEF in percentage

  15. Intra operative details; Mitral valve regurgitations [ Time Frame: 12 hours ]
    Grade of mitral valve regurgitations

  16. Intra operative details; Tricuspid valve regurgitations [ Time Frame: 12 hours ]
    Occurence of tricuspid vavle regurgitations

  17. Arterial blood gas lactate [ Time Frame: 6 hours ]
    Arterial blood gas lactate at 6 hours

  18. Arterial blood gas lactate [ Time Frame: 24 hours ]
    Arterial blood gas lactate at 24 hours

  19. Pro-BNP during follow up [ Time Frame: 1 year ]
    Pro-BNP at predefined time points during follow-up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria recipient:

  • Age ≥18 years
  • Signed informed consent form
  • Listed for heart transplantation

Inclusion criteria donor:

  • Age ≥18 and ≤70 years
  • Accepted as heart donor by the transplant team
  • (Research consent from the donor if required in country)

Exclusion Criteria recipient:

  • Previous solid organ transplantation
  • Grown-up congenital heart disease (GUCH)
  • Kidney failure eGFR<40 at listing, calculated by CDK-EPI Creatinine, or ultrafiltration or dialysis or rapidly deteriorating kidney function due to a diagnosed renal disease
  • Coagulopathy due to known hepatic disease or heparin induced thrombocytopenia
  • Subject diagnosed with Systemic Lupus Erythematous, sarcoidosis or amyloidosis
  • Known ongoing septicemia defined as positive blood culture immediately prior to the transplant (including with a durable VAD)
  • Incompatible blood group
  • Not able to understand the information provided during the informed consent procedure
  • Combined organ transplantation candidates
  • Subject already enrolled in another transplant related intervention study
  • Subjects under pre-transplant desensitization protocol (including plasma exchange in conjunction with the transplant surgery)
  • Mechanical circulatory support pre-transplantation (except durable Left ventricular assist device or Intra-aortic balloon pump)

Exclusion criteria donor:

  • Previous sternotomy
  • DCD hearts

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03991923


Contacts
Layout table for location contacts
Contact: Marina Fredholm, M.Sc. +46 (0)73-3929502 marina.fredholm@xvivogroup.com
Contact: Andreas Wallinder, MD, PhD +46 (0)73-5192142 andreas.wallinder@xvivogroup.com

Locations
Layout table for location information
Austria
Allgemeines Krankenhaus der Stadt Wien Recruiting
Wien, Austria
Contact: Andreas Zuckerman         
Belgium
UZ Leuven Recruiting
Leuven, Flemish Brabant, Belgium, 3000
Contact: Filip Rega    +3216344260    filip.rega@uzleuven.be   
France
Institut de cardiologie, Chirurgie thoracique et cardiovasculaire La Pitié Salpetrière Recruiting
Paris, Paris Cedex, France, 75651
Contact: Guillaume Lebreton         
Hôpital Bichat Claude-Bernard Recruiting
Paris, France
Contact: Marylou Para         
Germany
Klinikum der Universität München Recruiting
München, Bavaria, Germany, 81377
Contact: Sebastian Michel         
Deutschen Herzzentrum Berlin Recruiting
Berlin, Brandenburg, Germany, 13353
Contact: Christoph Knosalla         
Universitätsklinik der Ruhr-Universität Bochum Recruiting
Bad Oeynhausen, Germany
Contact: Rene Schramm         
Universitätsklinikum Düsseldorf Recruiting
Duesseldorf, Germany
Contact: Udo Boeken         
Hannover Medical School Recruiting
Hanover, Germany
Contact: Fabio Ius         
Italy
Azienda osedalaria di Padova Recruiting
Padova, Padova PD, Italy, 35121
Contact: Gino Gerosa         
Spain
Hospital Puerto de Hierro Recruiting
Madrid, Majadahonda Madrid, Spain, 28222
Contact: Alberto Forteza         
Sweden
Sahlgrenska University Hospital Recruiting
Gothenburg, Västra Götalands Regionen, Sweden, 412 34
Contact: Göran Dellgren         
United Kingdom
Freeman Hospital Not yet recruiting
Newcastle, Newcastle Upon Tyne, United Kingdom, NE77DN
Contact: Stephen Clark         
Queen Elisabeth Hospital Not yet recruiting
Birmingham, United Kingdom, B152TH
Contact: Aaron Ranasinghe         
Royal Papworth Hospital Not yet recruiting
Cambridge, United Kingdom
Contact: Marius Berman         
Sponsors and Collaborators
XVIVO Perfusion
Investigators
Layout table for investigator information
Principal Investigator: Filip Rega, MD, PhD UZ Leuven
Layout table for additonal information
Responsible Party: XVIVO Perfusion
ClinicalTrials.gov Identifier: NCT03991923    
Other Study ID Numbers: NIHP2019
First Posted: June 19, 2019    Key Record Dates
Last Update Posted: August 23, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by XVIVO Perfusion:
Non Ischemic Heart Preservation (NIHP)
Ischemic cold static storage of donor hearts (ICSS)